Background Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the
United States and worldwide, despite recent improvements in cancer management. CRC …

Abstract Background Wild type RAS (RAS-wt) status is predictive of the activities of the anti-
epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (C) and …

Background: We sought to clarify the prognostic impact of primary tumor location in
metastatic colorectal cancer (mCRC). Methods: We evaluated the association between …

The MAPK cascade plays a crucial role in tumor cell proliferation and survival. Accumulating
evidence suggests that mutations in the BRAF oncogene are not only associated with poor …

Purpose The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as
first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of …

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …

Background Following the discovery that mutant KRAS is associated with resistance to anti-
epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic …

BACKGROUND: It is hypothesized that BRAF mutant cancers represent a discrete subset of
metastatic colorectal cancer (CRC) defined by poorer survival. This study investigates …

BRAF mutation in colorectal cancer is associated with microsatellite instability (MSI) through
its relationship with high-level CpG island methylator phenotype (CIMP) and MLH1 promoter …

Purpose: BRAF-mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of
colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show …